HARMONY
Healthcare Alliance for Resourceful Medicines
Offensive against Neoplasms in Hematology

Big Data (analytics) to enable better and faster treatment for Patients with Hematologic Malignancies.

<u>Interactive Session</u> at the 23rd Congress of EHA

Invitation to participate

Date   Saturday, 16th June 2018
Time frame   14:45 to 16:15 hrs.
Venue   Room K2, Auditorium, Stockholm International Fairs, Sweden

It's all about Big Data in Hematology. Your Big Data!

Big Data will have an impact on health and in particular on the development of new drugs and therapies for patients. Blood cancers, or hematologic cancers (e.g. leukemia, lymphoma, and myeloma), affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, resulting in limitations for patient access to the best healthcare. The HARMONY Alliance aims to use "Big Data and Big Data analytics" to deliver information that will help to improve the care of patients with these diseases. HARMONY: Ready to collect data and deliver outcomes.

Let's connect

— Participate in our **Interactive Session:** Open for Clinicians, Researchers, Data Providers, and Patient and nurses' organizations. We will update you on HARMONY's latest steps and achievements.
— June 16 | Room K2 | 14:45-16:15

— Join us at our **Partnering session**: Open for organizations interested to become a data provider. We will inform you about the opportunities and the guidelines.
— June 16 | Room K11 | 16:15–17:15

— Visit us at the exhibition! You can find us in **booth** nr. **1284.**

Session Program

HARMONY: Ready to collect data and deliver outcomes

Start 14:45   **Welcome and Introduction**
— Pieter Sonneveld, ErasmusMC, President EHA

HARMONY: First year achievements
— Guillermo Sanz, HARMONY Co-Chair, HULAFE, Spain.
— Pam Bacon, HARMONY Project Co-Leader, CELGENE, Switzerland

Introducing the HARMONY Data Platform

Data management and Analysis
— Michel van Speybroeck, Janssen, Belgium & Work Package 3 Lead
— Ana Heredia, GMV, Spain & Work Package 3 Lead

Legal aspects of Data Protection in HARMONY
— John Butler, WP8 Lead, Bayer, Germany

HARMONY: Unlocking valuable knowledge

Overview of "Bench-to-Bedside" Pilot Projects
— Lars Bullinger, WP2 Lead, Charité, Germany
— Aliki Taylor, Takeda, United Kingdom

AML: Leading the way: the first results
— Harmut Döhner, UULM, Germany
— Estella Mendelson, Novartis, USA

CLL: The second successful Pilot Study
— Lesley Ann Sutton, European research Initiative on CLL, Italy

Update of the MM Project
— Pieter Sonneveld, ErasmusMC, The Nederlands
— Bruno Costa, Celgene, Switzerland

Update of the APL Project
— Francesco Lo Coco, University of Rome Tor Vergata, Italy

HARMONY: Future Plans
— Jesús María Hernández, HARMONY Co-ordinator, IBSAL, Spain
— Mirko Vukcevic, HARMONY Project Leader, Novartis, Switzerland

End 16:15 hrs. Interested to become a data provider? You are invited to join us at
our **Partnering session**: Room K11 | 16:15–17:15.

About the HARMONY Alliance:
Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology

The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 53 public and private partners. Our goal is unlocking valuable knowledge on hematologic malignancies (HMs).
The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Approach:
— Collect, share, and harmonize Big Data from high-quality multidisciplinary sources.
— Assess and integrate a large amount of molecular data to better understand outcomes in specific hematological malignancies.
— Generate evidence to encourage healthcare systems to pay particular attention to the value of healthcare and to improve outcomes.
— Facilitate drug development pipelines and accelerate the "bench-to-bedside" process in drug development.

Focus:
— Multiple myeloma (MM), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Myelodysplastic Syndromes (MDS), and Pediatric Hematologic Malignancies.

Budget:
— 40 M€

Duration:
— 2017 - 2021

Contact:
— HARMONY Coordination Office
Institute of BioMedical Research of Salamanca (IBSAL), Salamanca, Spain
Phone: +34 616 222 324 | E-mail: harmonyoffice@ibsal.es

— HARMONY Communications Office
European Hematology Association (EHA), The Hague, the Netherlands
Phone: +31 70 302 0099 | E-mail: communications@harmony-alliance.eu

www.harmony-alliance.eu | @harmonyNetEU